Patent SG-11201905812W-A (SG)
Title: Azolopyrimidine for the treatment of cancer-related disorders
Inventor: BEATTY JOEL
IPC: C07D403/04
Filed: 2018-01-19
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIPO I PCT (51) International Patent Classification: A61K 31/506 (2006.01) C07D 401/14 (2006.01) A61K 31/4192 (2006.01) C07D 403/04 (2006.01) (21) International Application Number: PCT/US2018/014352 (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/448,608 20 January 2017 (20.01.2017) US 62/479,005 30 March 2017 (30.03.2017) US (71) Applicant: ARCUS BIOSCIENCES, INC. [US/US]; 3928 Point Eden Way, Hayward, CA 94545 (US). (72) Inventors: BEATTY, Joel; 2246 Southampton Way, San Mateo, CA 94403 (US). DEBIEN, Laurent; 461 Andover Street, San Francisco, CA 94110 (US). JEFFREY, Jenna; 5375 Broadway, Oakland, CA 94618 (US). LELETI, Man- mohan, Reddy; 4206 Kelton Street, Dublin, CA 94568 (US). MANDAL, Debashis; 405 Rancho Arroyo Parkway, Apt. 326, Fremont, CA 94536 (US). MILES, Dillon; 2320 Haste Street, #14, Berkeley, CA 94074 (US). POWERS, Jay; 745 Rockaway Beach Avenue, Pacifica, CA 94044 (US). ROSEN, Brandon; 2321 Hacienda Street, San Ma- teo, CA 94403 (US). THOMAS-TRAN, Rhiannon; 4986 Chiles Drive, San Jose, CA 95136 (US). SHARIF, Ehesan; 1793 Santa Cruz Avenue, Menlo Park, CA 94025 (US). (74) Agent: DOLAN, Gregory, F. et al.; Mintz Levin Cohn Fer- ris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1-1 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, O GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, O N er) (54) Title: AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS 00 1-1 the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the (57) : Compound that is an inhibitor of at least one of the A 2A and A 2B adenosine receptors, and compositions containing O treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A receptor and/or the adenosine A 2A 2B receptor. C Hu omit °nolo monlioluo oimIE (10) International Publication Number WO 2018/136700 Al 19 January 2018 (19.01.2018) English English Published: with international search report (Art. 21(3))